Isomorphic Labs, the Alphabet spinoff, released IsoDDE on February 10, a unified drug design engine that achieves a 50% success rate on the hardest molecular prediction tasks, outperforming AlphaFold …
Bristol Myers Squibb is expanding its partnership with Nvidia to boost AI computing power for drug discovery, building on its AI Center of Excellence using Nvidia's DGX SuperPOD infrastructure that ha…
Chai Discovery Inc. has raised $400 million in Series C funding, nearly tripling its valuation to $3.8 billion, as the AI drug discovery company signs licensing agreements with Pfizer Inc., Eli Lilly …
Google DeepMind and Isomorphic Labs have announced a joint initiative on bioresilience, using AI to predict and defend against biological threats, building on AlphaFold technology. Isomorphic Labs, fo…
Chai Discovery raised $400 million in a Series C round led by Index Ventures, tripling its valuation to $3.8 billion in seven months as the AI drug discovery startup's generative models are deployed a…
OpenAI researcher Miles Wang is in advanced talks to launch an AI drug discovery startup at a $2 billion valuation, with Lightspeed Venture Partners reportedly leading a $200 million round, according …
Chai Discovery has raised $400 million in a Series C round at a $3.8 billion valuation, tripling its valuation in seven months. The OpenAI-backed drug discovery startup, founded in 2024, builds AI mod…
OpenAI-backed Chai Discovery closed a $400 million funding round at a $3.8 billion valuation on July 14, tripling its price tag in seven months. The Index Ventures-led round positions the company as A…
Palantir CEO Alex Karp described AI's impact on the pharmaceutical industry as a 'fucking nuclear weapon,' arguing that AI will collapse incumbents' data advantages and democratize drug discovery. Cri…
Alchemab Therapeutics secured a £25 million investment from the British Business Bank, the largest life sciences bet by the state-owned lender. The funding will expand the company's AI-driven antibody…
Wall Street fell on Tuesday as semiconductor stocks slumped after Samsung's mixed earnings, with the Dow Jones down 0.3%, S&P 500 down 0.3%, and Nasdaq Composite down 0.7%. Investors rotated into defe…
Nvidia launched its BioNeMo Agent Toolkit at the BIO International Convention on June 23, enabling AI agents to autonomously handle complex scientific workflows in drug discovery. Certara is among the…
Eli Lilly invested $40 million in Absci Corporation to advance ABS-201, an AI-designed injectable antibody targeting hair loss and endometriosis. The investment was part of a $100 million equity round…
Eli Lilly invested $40 million in Absci, a generative AI drug company, to develop ABS-201, an injectable antibody for baldness and endometriosis. The deal, part of a $100 million stock offering, aims …
Stockholmsbörsen öppnar avvaktande efter en stark period på Wall Street, där teknikaktier drev Nasdaq upp 1,5 procent. SEB konstaterar att marknaden har sett igenom geopolitisk oro och satsat stort på…
NVIDIA turned its BioNeMo life-sciences stack into an agent toolkit, allowing AI agents to call accelerated models and libraries for scientific tasks. Anthropic's Claude Science workbench is the first…
Six leading UK fund managers revealed underrated stocks with long-term growth potential, including Eli Lilly, Lion Finance Group, Frasers Group, RELX, and Bloom Energy, spanning healthcare, financial …
Nvidia and Genentech executives made the case for AI-driven drug discovery at BIO2026, highlighting their partnership that combines Genentech's biological data with Nvidia's computing infrastructure. …
Insilico Medicine and SK Biopharmaceuticals announced a partnership valued at over $2.5 billion to use AI for developing neuroimmune therapies. Insilico will leverage its Pharma.AI platform for drug d…
GLP-1 drug use peaks in middle age, with 22% of adults aged 50-64 taking them, then drops sharply to 9% at age 65 due to Medicare's ban on covering weight-loss medications. The overall adult usage rat…